UK markets closed

Sarepta Therapeutics, Inc. (0L35.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
118.49+3.69 (+3.22%)
At close: 05:55PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.95
52-week change 3-18.01%
S&P500 52-week change 323.06%
52-week high 3155.48
52-week low 355.68
50-day moving average 3121.03
200-day moving average 3112.45

Share statistics

Avg vol (3-month) 3424
Avg vol (10-day) 3365
Shares outstanding 566.82M
Implied shares outstanding 6N/A
Float 889.61M
% held by insiders 14.30%
% held by institutions 187.76%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -43.11%
Operating margin (ttm)6.21%

Management effectiveness

Return on assets (ttm)-5.24%
Return on equity (ttm)-86.15%

Income statement

Revenue (ttm)1.24B
Revenue per share (ttm)13.46
Quarterly revenue growth (yoy)53.50%
Gross profit (ttm)N/A
EBITDA -223.43M
Net income avi to common (ttm)-535.98M
Diluted EPS (ttm)-4.28
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.68B
Total cash per share (mrq)17.86
Total debt (mrq)1.4B
Total debt/equity (mrq)162.55%
Current ratio (mrq)3.95
Book value per share (mrq)9.17

Cash flow statement

Operating cash flow (ttm)-500.99M
Levered free cash flow (ttm)-347.96M